Medicure (MPH) Investor presentation summary

Strategic focus and growth initiatives

• Emphasis on expanding sales of ZYPITAMAG, AGGRASTAT, and Marley Drug pharmacy subsidiary.

• Completion of Phase 3 trial for MC-1 targeting rare pediatric disease to obtain a priority review voucher.

• Initiation of pre-clinical development for new chemical entities based on pyridoxal 5'-phosphate analogues.

• Growth strategy includes reinvesting profits into R&D and acquisitions, with a focus on building the pharmacy business and developing new drugs for unmet needs.

• Recent acquisitions of Gateway Medical Pharmacy and West Olympia Pharmacy to enhance distribution and marketing efficiency.

Financial performance and key metrics

• Net revenue projected to grow from 2023 to 2025, with contributions from AGGRASTAT, ZYPITAMAG, and pharmacy business.

• R&D expenses remain steady, with a notable cash outflow in 2025 due to pharmacy acquisitions.

• EBITDA and net loss figures indicate ongoing investment in growth, with negative net cash change in 2025.

Product highlights and market positioning

• ZYPITAMAG achieved $6.5M in 2025 sales, up 5% year-over-year, targeting the $4B statin market.

• Marley Drug pharmacy generated $20.3M in 2025, up 188% from the prior year, expanding direct-to-consumer reach.

• AGGRASTAT sales declined 29% to $5.7M in 2025, but remains a leading IV antiplatelet used in over 1,000 hospitals.